Caitlin Philpy, NP
Primary Care · la Junta, CONPI 1609354414
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 27.4% of the total. Reporting peaked in 2022 at $697 and has fallen 83.1% since, to $118 in 2025.
Across 97 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$436
- Novo Nordisk$231
- Lilly USA, LLC$158
- Pfizer$108
- Amgen$104
- Merck$92
- plus $464 from 15 others
What the payments were for
- Food & beverage$1,593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $436 |
| Novo Nordisk | 14 | $231 |
| Lilly USA, LLC | 10 | $158 |
| Pfizer | 7 | $108 |
| Amgen | 6 | $104 |
| Merck | 5 | $92 |
| AstraZeneca | 5 | $75 |
| Neurocrine Biosciences, Inc. | 4 | $66 |
| Novartis | 3 | $47 |
| Exact Sciences | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Edwards Lifesciences | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$1,593 in reported general payments places this provider in the 80th percentile of 112 primary care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 26 | $28,191 |
| JardianceEmpagliflozin | 17 | $24,160 |
| TrulicityDulaglutide | 18 | $21,489 |
| MounjaroTirzepatide | 20 | $20,754 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,242 |
| OzempicSemaglutide | 11 | $15,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,647 |
| XareltoRivaroxaban | 16 | $12,596 |
| EliquisApixaban | 12 | $11,323 |
| BelsomraSuvorexant | 17 | $7,529 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,062 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,060 |
| Potassium Chloride | 72 | $1,423 |
| Losartan Potassium | 90 | $1,252 |
| Fentanyl | 11 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $231 | $44,15837 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $42,24338 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $16 | $30,22230 claims |
| AstraZenecaBreztri Aerosphere | $75 | $17,24227 claims |
| GSKTrelegy Ellipta | $12 | $12,64719 claims |
| PfizerEliquis | $108 | $11,32312 claims |
| MerckBelsomra | $92 | $7,52917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 primary care providers in Colorado.
Other primary care in la Junta
- Missouri Krantzla Junta$2K
- Laura CarlsenLittleton$22K
- Kendra PayneCastle Rock$22K
- Kaitlin KrausDenver$16K
- Emily WillmannThornton$4K
- Tracy RasmussenParker$4K
- Linda MyersGrand Junction$4K
- Kathryn PalmerGreeley$4K
- Leah BrownFort Morgan$3K
- Diana Rodriguez OrtizAurora$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.